The Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 May 2002The Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial ALVIN M. MATSUMOTO, LISA TENOVER, MICHAEL McCLUNG, DAVID MOBLEY, JACK GELLER, MICHAEL SULLIVAN, JOHN GRAYHACK, HUNTER WESSELLS, DOV KADMON, MALACHI FLANAGAN, GANG K. ZHANG, JOSEPH SCHMIDT, ALICE M. TAYLOR, MICHAEL LEE, JOANNE WALDSTREICHER, and FOR THE PLESS STUDY GROUP† ALVIN M. MATSUMOTOALVIN M. MATSUMOTO Financial interest and/or other relationship with Merck & Co., Inc. More articles by this author , LISA TENOVERLISA TENOVER More articles by this author , MICHAEL McCLUNGMICHAEL McCLUNG More articles by this author , DAVID MOBLEYDAVID MOBLEY Financial interest and/or other relationship with Merck & Co., Inc. More articles by this author , JACK GELLERJACK GELLER More articles by this author , MICHAEL SULLIVANMICHAEL SULLIVAN More articles by this author , JOHN GRAYHACKJOHN GRAYHACK More articles by this author , HUNTER WESSELLSHUNTER WESSELLS More articles by this author , DOV KADMONDOV KADMON More articles by this author , MALACHI FLANAGANMALACHI FLANAGAN More articles by this author , GANG K. ZHANGGANG K. ZHANG More articles by this author , JOSEPH SCHMIDTJOSEPH SCHMIDT More articles by this author , ALICE M. TAYLORALICE M. TAYLOR Financial interest and/or other relationship with Merck & Co., Inc. More articles by this author , MICHAEL LEEMICHAEL LEE Financial interest and/or other relationship with Merck & Co., Inc. More articles by this author , JOANNE WALDSTREICHERJOANNE WALDSTREICHER Financial interest and/or other relationship with Merck & Co., Inc. More articles by this author , and FOR THE PLESS STUDY GROUP† More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65095-1AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determine the effect of long-term suppression of dihydrotestosterone with finasteride, a specific type II 5α-reductase inhibitor, on bone mineral density. Materials and Methods: As part of a large (3,040 cases) 4-year, double-blind, placebo controlled trial designed to assess the long-term effects of finasteride in men with benign prostatic hyperplasia, 157 men 46 to 76 years old who were randomized to receive either 5 mg. finasteride or placebo underwent dual energy x-ray absorptiometry of the lumbar spine at baseline and at years 2, 3 and 4. Results: Of 117 patients who had a baseline measurement and at least 1 additional measurement during the study baseline mean plus or minus standard deviation bone mineral density values were 1.12 ± 0.17 gm./cm.2 in the finasteride group (63) and 1.10 ± 0.17 gm./cm.2 in the placebo group (54). After 4 years bone mineral density was not different between treatment groups (finasteride 1.14 ± 0.17 gm./cm.2 and placebo 1.13 ± 0.18 gm./cm.2). Similar results were obtained for the 33 finasteride and 25 placebo treated patients who completed the study with year 4 bone mineral density measurements. Conclusions: These data demonstrate that long-term inhibition of type II 5α-reductase with finasteride does not adversely affect bone mineral density. References 1 : The localization of androgen receptors in human bone. J Clin Endocrinol Metab1997; 82: 3493. Google Scholar 2 : Androgens and bone. Calcif Tissue Int1995; 56: 341. Google Scholar 3 : Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab1996; 81: 4358. Google Scholar 4 : Osteoporosis in men. Endocrinol Metab Clin North Am1998; 27: 349. Google Scholar 5 : Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol2000; 163: 181. Link, Google Scholar 6 : Steroid formation in osteoblast-like cells. J Int Med Res1998; 26: 1. Google Scholar 7 : Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology1998; 52: 195. Google Scholar 8 : The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med1998; 338: 557. Google Scholar 9 : The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med1992; 327: 1185. Google Scholar 10 : The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol1992; 147: 1298. Link, Google Scholar 11 : Bone density is normal in male rats treated with finasteride. Endocrinology1995; 136: 1381. Google Scholar 12 : Prolonged treatment with finasteride (a 5α-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol1992; 37: 432. Google Scholar 13 : Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia—a clinical research center study. J Clin Endocrinol Metab1996; 81: 1031. Google Scholar 14 : Male pseudohermaphroditism due to steroid 5α-reductase deficiency. Am J Med1977; 62: 170. Google Scholar 15 : Familial incomplete pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med1974; 291: 944. Google Scholar 16 : Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med1994; 331: 1056. Google Scholar 17 : Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med1997; 337: 91. Google Scholar 18 : Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens. J Clin Invest1997; 100: 1755. Google Scholar 19 : Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab1990; 70: 1136. Google Scholar 20 : Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporosis Int1997; 7: 564. Google Scholar From the VA Puget Sound Health Care System and University of Washington, Seattle, Washington, Emory University, Atlanta, Georgia, Oregon Osteoporosis Center, Portland, Oregon, Research for Health, Inc, Houston, Texas, Mercy Research Clinic, San Diego, California, Northwestern University, Chicago, Illinois, University of Arizona, Tucson, Arizona, Baylor College of Medicine, Houston, Texas, Rush Presbyterian Medical Center, Chicago, Illinois, Park Nicollet Clinic, Minneapolis, Minnesota, University of California, San Diego, California, and Merck & Co., Inc., Rahway, New Jersey© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byAmory J, Anawalt B, Matsumoto A, Page S, Bremner W, Wang C, Swerdloff R and Clark R (2018) The Effect of 5α-Reductase Inhibition With Dutasteride and Finasteride on Bone Mineral Density, Serum Lipoproteins, Hemoglobin, Prostate Specific Antigen and Sexual Function in Healthy Young MenJournal of Urology, VOL. 179, NO. 6, (2333-2338), Online publication date: 1-Jun-2008.ANDRIOLE G, BRUCHOVSKY N, CHUNG L, MATSUMOTO A, RITTMASTER R, ROEHRBORN C, RUSSELL D and TINDALL D (2018) DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 172, NO. 4 Part 1, (1399-1403), Online publication date: 1-Oct-2004. Volume 167Issue 5May 2002Page: 2105-2108 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsfinasteridestanolonebone densityprostatic hyperplasiaMetricsAuthor Information ALVIN M. MATSUMOTO Financial interest and/or other relationship with Merck & Co., Inc. More articles by this author LISA TENOVER More articles by this author MICHAEL McCLUNG More articles by this author DAVID MOBLEY Financial interest and/or other relationship with Merck & Co., Inc. More articles by this author JACK GELLER More articles by this author MICHAEL SULLIVAN More articles by this author JOHN GRAYHACK More articles by this author HUNTER WESSELLS More articles by this author DOV KADMON More articles by this author MALACHI FLANAGAN More articles by this author GANG K. ZHANG More articles by this author JOSEPH SCHMIDT More articles by this author ALICE M. TAYLOR Financial interest and/or other relationship with Merck & Co., Inc. More articles by this author MICHAEL LEE Financial interest and/or other relationship with Merck & Co., Inc. More articles by this author JOANNE WALDSTREICHER Financial interest and/or other relationship with Merck & Co., Inc. More articles by this author FOR THE PLESS STUDY GROUP† More articles by this author Expand All Advertisement PDF downloadLoading ...